Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 334

1.

Imaging spectrum of Bing-Neel syndrome: how can a radiologist recognise this rare neurological complication of Waldenström's macroglobulinemia?

Fitsiori A, Fornecker LM, Simon L, Karentzos A, Galanaud D, Outteryck O, Vermersch P, Pruvo JP, Gerardin E, Lebrun-Frenay C, Lafitte F, Cottier JP, Clerc C, de Seze J, Dietemann JL, Kremer S.

Eur Radiol. 2018 Jun 19. doi: 10.1007/s00330-018-5543-7. [Epub ahead of print]

PMID:
29922935
2.

Focal and diffuse cervical spinal cord damage in patients with early relapsing-remitting MS: A multicentre magnetisation transfer ratio study.

Combès B, Kerbrat A, Ferré JC, Callot V, Maranzano J, Badji A, Le Page E, Labauge P, Ayrignac X, Carra Dallière C, de Champfleur NM, Pelletier J, Maarouf A, de Seze J, Collongues N, Brassat D, Durand-Dubief F, Barillot C, Bannier E, Edan G; EMISEP Study Group.

Mult Scler. 2018 Jun 1:1352458518781999. doi: 10.1177/1352458518781999. [Epub ahead of print]

PMID:
29909771
3.

Demyelinating diseases.

Lebrun C, de Seze J.

Rev Neurol (Paris). 2018 Jun;174(6):355. doi: 10.1016/j.neurol.2018.04.007. No abstract available.

PMID:
29903398
4.

An autophagy-targeting peptide to treat chronic inflammatory demyelinating polyneuropathies.

Brun S, Schall N, Bonam SR, Bigaut K, Mensah-Nyagan AG, de Sèze J, Muller S.

J Autoimmun. 2018 Jun 5. pii: S0896-8411(18)30236-1. doi: 10.1016/j.jaut.2018.05.009. [Epub ahead of print]

PMID:
29884340
5.

MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study.

Tourbah A, Gout O, Vighetto A, Deburghgraeve V, Pelletier J, Papeix C, Lebrun-Frenay C, Labauge P, Brassat D, Toosy A, Laplaud DA, Outteryck O, Moreau T, Debouverie M, Clavelou P, Heinzlef O, De Sèze J, Defer G, Sedel F, Arndt C.

CNS Drugs. 2018 May 28. doi: 10.1007/s40263-018-0528-2. [Epub ahead of print]

PMID:
29808469
6.

Testosterone and estrogen in multiple sclerosis: from pathophysiology to therapeutics.

Collongues N, Patte-Mensah C, De Seze J, Mensah-Nyagan AG, Derfuss T.

Expert Rev Neurother. 2018 Jun;18(6):515-522. doi: 10.1080/14737175.2018.1481390. Epub 2018 Jun 6.

PMID:
29799288
7.

MOG encephalomyelitis: international recommendations on diagnosis and antibody testing.

Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, Kümpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG, Wildemann B.

J Neuroinflammation. 2018 May 3;15(1):134. doi: 10.1186/s12974-018-1144-2. Review.

8.

Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study.

Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, Ciron J, Collongues N, Brassat D, Cotton F, Papeix C, Durand-Dubief F, Laplaud D, Deschamps R, Cohen M, Biotti D, Ayrignac X, Tilikete C, Thouvenot E, Brochet B, Dulau C, Moreau T, Tourbah A, Lebranchu P, Michel L, Lebrun-Frenay C, Montcuquet A, Mathey G, Debouverie M, Pelletier J, Labauge P, Derache N, Coustans M, Rollot F, De Seze J, Vukusic S, Marignier R; OFSEP and NOMADMUS Study Group.

Neurology. 2018 May 22;90(21):e1858-e1869. doi: 10.1212/WNL.0000000000005560. Epub 2018 Apr 25.

PMID:
29695592
9.

The effect of oxysterols on nerve impulses.

Bezine M, Namsi A, Sghaier R, Ben Khalifa R, Hamdouni H, Brahmi F, Badreddine I, Mihoubi W, Nury T, Vejux A, Zarrouk A, de Sèze J, Moreau T, Nasser B, Lizard G.

Biochimie. 2018 Apr 21. pii: S0300-9084(18)30100-7. doi: 10.1016/j.biochi.2018.04.013. [Epub ahead of print] Review.

PMID:
29684511
10.

Late activity rebound in non-active multiple sclerosis: A rare event.

Corti L, Ayrignac X, Carra Dalliere C, Charif M, de Sèze J, Biotti D, Ciron J, Labauge P.

Mult Scler. 2018 Mar 1:1352458518765670. doi: 10.1177/1352458518765670. [Epub ahead of print] No abstract available.

PMID:
29533160
11.

FDG PET and MRI Findings in a Case of Bing-Neel Syndrome.

Bund C, Lhermitte B, De Seze J, Kremer S, Namer IJ.

Clin Nucl Med. 2018 Apr;43(4):262-264. doi: 10.1097/RLU.0000000000002019.

PMID:
29465488
12.

Modulation of Kv3.1b potassium channel level and intracellular potassium concentration in 158N murine oligodendrocytes and BV-2 murine microglial cells treated with 7-ketocholesterol, 24S-hydroxycholesterol or tetracosanoic acid (C24:0).

Bezine M, Maatoug S, Ben Khalifa R, Debbabi M, Zarrouk A, Wang Y, Griffiths WJ, Nury T, Samadi M, Vejux A, de Sèze J, Moreau T, Kharrat R, El Ayeb M, Lizard G.

Biochimie. 2018 Feb 17. pii: S0300-9084(18)30043-9. doi: 10.1016/j.biochi.2018.02.008. [Epub ahead of print]

PMID:
29462682
13.

Ozone, NO2 and PM10 are associated with the occurrence of multiple sclerosis relapses. Evidence from seasonal multi-pollutant analyses.

Jeanjean M, Bind MA, Roux J, Ongagna JC, de Sèze J, Bard D, Leray E.

Environ Res. 2018 May;163:43-52. doi: 10.1016/j.envres.2018.01.040. Epub 2018 Feb 6.

14.

Quantitative and qualitative normative dataset for intraepidermal nerve fibers using skin biopsy.

Collongues N, Samama B, Schmidt-Mutter C, Chamard-Witkowski L, Debouverie M, Chanson JB, Antal MC, Benardais K, de Seze J, Velten M, Boehm N.

PLoS One. 2018 Jan 25;13(1):e0191614. doi: 10.1371/journal.pone.0191614. eCollection 2018.

15.

Metabolomics approaches in experimental allergic encephalomyelitis.

Battini S, Bund C, Moussallieh FM, Çiçek AE, De Sèze J, Namer IJ.

J Neuroimmunol. 2018 Jan 15;314:94-100. doi: 10.1016/j.jneuroim.2017.11.018. Epub 2017 Dec 2.

PMID:
29224959
16.

MOG-antibody neuromyelitis optica spectrum disorder: is it a separate disease?

de Seze J.

Brain. 2017 Dec 1;140(12):3072-3075. doi: 10.1093/brain/awx292. No abstract available.

PMID:
29194504
17.

Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?

Rouzaud C, Hautecoeur P, Donze C, Heinzlef O, Dinh A; Club Francophone de la Sclérose en Plaque, Creange A, Abdullatif A, Audouin B, Tourbah A, Berger E, Bourre B, Brochet B, Mekies C, Cabre P, Papeix C, Casez O, Brassat D, Defer G, Derache N, De Seze J, Dive D, LePage E, Fromont A, Gouider R, Edan G, Pelletier J, Grimaud J, Guennoc AM, Camdessanché JP, Kwiatkowski A, Laplaud D, Lebrun C, Debouverie M, Coustans M, Gout O, La Rochelle OA, Heinzlef O, Ouallet JC, Cavelou P, Hautecoeur P, Labauge P, Vermersch P, Wiertlewski S, Vukusic S, Marignier R, Schluep M, Seeldrayers P, Slassi I, Stankoff B, Thaite F, Moreau T, Thouvenot E, Zephir H, Ciron J, Collongues N, Kerschen P, Cohen M, Gueguen A, Mathey G, Carra C, Bernady P, Faucheux JM, Planque E, Donze C, Ruet A, Mouzawakh C, Pittion S.

Mult Scler Relat Disord. 2017 Nov;18:161-163. doi: 10.1016/j.msard.2017.08.009. Epub 2017 Aug 24. No abstract available.

PMID:
29141801
18.

Is the Choosing Wisely® campaign model applicable to the management of multiple sclerosis in France? A GRESEP pilot study.

Trumbic B, Zéphir H, Ouallet JC, Le Page E, Laplaud D, Bensa C, de Sèze J.

Rev Neurol (Paris). 2018 Jan - Feb;174(1-2):28-35. doi: 10.1016/j.neurol.2017.06.016. Epub 2017 Nov 8.

PMID:
29128151
19.

Multiple sclerosis treatments and the anti-JCV antibody index.

de Seze J, Lebrun-Frenay C.

Rev Neurol (Paris). 2017 Dec;173(10):e1. doi: 10.1016/j.neurol.2017.09.008. Epub 2017 Nov 2. No abstract available.

PMID:
29103667
20.

Early intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with onconeural antibodies.

Berzero G, Karantoni E, Dehais C, Ducray F, Thomas L, Picard G, Rogemond V, Candelier G, Camdessanché JP, Antoine JC, De Seze J, Liou-Schischmanoff A, Honnorat J, Delattre JY, Psimaras D.

J Neurol Neurosurg Psychiatry. 2018 Jul;89(7):789-792. doi: 10.1136/jnnp-2017-316904. Epub 2017 Oct 30. No abstract available.

21.

Radiologically isolated syndrome in children: Clinical and radiologic outcomes.

Makhani N, Lebrun C, Siva A, Brassat D, Carra Dallière C, de Seze J, Du W, Durand Dubief F, Kantarci O, Langille M, Narula S, Pelletier J, Rojas JI, Shapiro ED, Stone RT, Tintoré M, Uygunoglu U, Vermersch P, Wassmer E, Okuda DT, Pelletier D.

Neurol Neuroimmunol Neuroinflamm. 2017 Sep 25;4(6):e395. doi: 10.1212/NXI.0000000000000395. eCollection 2017 Nov.

22.

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.

Plavina T, Muralidharan KK, Kuesters G, Mikol D, Evans K, Subramanyam M, Nestorov I, Chen Y, Dong Q, Ho PR, Amarante D, Adams A, De Sèze J, Fox R, Gold R, Jeffery D, Kappos L, Montalban X, Weinstock-Guttman B, Hartung HP, Cree BAC.

Neurology. 2017 Oct 10;89(15):1584-1593. doi: 10.1212/WNL.0000000000004485. Epub 2017 Sep 15.

23.

The translocator protein ligand XBD173 improves clinical symptoms and neuropathological markers in the SJL/J mouse model of multiple sclerosis.

Leva G, Klein C, Benyounes J, Hallé F, Bihel F, Collongues N, De Seze J, Mensah-Nyagan AG, Patte-Mensah C.

Biochim Biophys Acta. 2017 Dec;1863(12):3016-3027. doi: 10.1016/j.bbadis.2017.09.007. Epub 2017 Sep 9.

PMID:
28899788
24.

High-intensity interval training combined with resistance training improves physiological capacities, strength and quality of life in multiple sclerosis patients: a pilot study.

Zaenker P, Favret F, Lonsdorfer E, Muff G, de Seze J, Isner-Horobeti ME.

Eur J Phys Rehabil Med. 2018 Feb;54(1):58-67. doi: 10.23736/S1973-9087.17.04637-8. Epub 2017 Jul 5.

25.

Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy.

Fissolo N, Pignolet B, Matute-Blanch C, Triviño JC, Miró B, Mota M, Perez-Hoyos S, Sanchez A, Vermersch P, Ruet A, de Sèze J, Labauge P, Vukusic S, Papeix C, Almoyna L, Tourbah A, Clavelou P, Moreau T, Pelletier J, Lebrun-Frenay C, Montalban X, Brassat D, Comabella M; Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment (BIONAT), Best EScalation Treatment in Multiple Sclerosis (BEST-MS), and the Société Francophone de la Sclérose En Plaques (SFSEP) Network.

Ann Neurol. 2017 Aug;82(2):186-195. doi: 10.1002/ana.24987. Epub 2017 Jul 22.

PMID:
28681388
26.

Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome.

Maillart E, Vidal JS, Brassat D, Stankoff B, Fromont A, de Sèze J, Taithe F, Clavelou P, Bourre B, Delvaux V, Rico A, Labauge P, Tourbah A, Lebrun C, Pelletier J, Moreau T, Louapre C, Lubetzki C, Papeix C.

Neurol Neuroimmunol Neuroinflamm. 2017 Apr 14;4(3):e346. doi: 10.1212/NXI.0000000000000346. eCollection 2017 May.

27.

Autophagy in neuroinflammatory diseases.

Muller S, Brun S, René F, de Sèze J, Loeffler JP, Jeltsch-David H.

Autoimmun Rev. 2017 Aug;16(8):856-874. doi: 10.1016/j.autrev.2017.05.015. Epub 2017 May 29. Review.

PMID:
28572049
28.

Biotherapy in Inflammatory Diseases of the CNS: Current Knowledge and Applications.

Collongues N, Michel L, de Seze J.

Curr Treat Options Neurol. 2017 May;19(5):19. doi: 10.1007/s11940-017-0456-3. Review.

PMID:
28417344
29.

Air pollution by particulate matter PM10 may trigger multiple sclerosis relapses.

Roux J, Bard D, Le Pabic E, Segala C, Reis J, Ongagna JC, de Sèze J, Leray E.

Environ Res. 2017 Jul;156:404-410. doi: 10.1016/j.envres.2017.03.049. Epub 2017 Apr 11.

PMID:
28407574
30.

Evidence of K+ homeostasis disruption in cellular dysfunction triggered by 7-ketocholesterol, 24S-hydroxycholesterol, and tetracosanoic acid (C24:0) in 158N murine oligodendrocytes.

Bezine M, Debbabi M, Nury T, Ben-Khalifa R, Samadi M, Cherkaoui-Malki M, Vejux A, Raas Q, de Sèze J, Moreau T, El-Ayeb M, Lizard G.

Chem Phys Lipids. 2017 Oct;207(Pt B):135-150. doi: 10.1016/j.chemphyslip.2017.03.006. Epub 2017 Mar 18.

PMID:
28322741
31.

Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis.

Brochet B, Deloire MS, Perez P, Loock T, Baschet L, Debouverie M, Pittion S, Ouallet JC, Clavelou P, de Sèze J, Collongues N, Vermersch P, Zéphir H, Castelnovo G, Labauge P, Lebrun C, Cohen M, Ruet A; PROMESS study investigators.

PLoS One. 2017 Jan 3;12(1):e0168834. doi: 10.1371/journal.pone.0168834. eCollection 2017.

32.

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21.

33.

Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease.

Juryńczyk M, Tackley G, Kong Y, Geraldes R, Matthews L, Woodhall M, Waters P, Kuker W, Craner M, Weir A, DeLuca GC, Kremer S, Leite MI, Vincent A, Jacob A, de Sèze J, Palace J.

J Neurol Neurosurg Psychiatry. 2017 Feb;88(2):132-136. doi: 10.1136/jnnp-2016-314005. Epub 2016 Oct 8.

PMID:
27951522
34.

Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders.

Montcuquet A, Collongues N, Papeix C, Zephir H, Audoin B, Laplaud D, Bourre B, Brochet B, Camdessanche JP, Labauge P, Moreau T, Brassat D, Stankoff B, de Seze J, Vukusic S, Marignier R; NOMADMUS study group and the Observatoire Français de la Sclérose en Plaques (OFSEP).

Mult Scler. 2017 Sep;23(10):1377-1384. doi: 10.1177/1352458516678474. Epub 2016 Nov 25.

PMID:
27885065
35.

Chronic inflammatory demyelinating polyradiculoneuropathy: A new animal model for new therapeutic targets.

de Sèze J, Kremer L, Alves do Rego C, Taleb O, Lam D, Beiano W, Mensah-Nyagan G, Trifilieff E, Brun S.

Rev Neurol (Paris). 2016 Dec;172(12):767-769. doi: 10.1016/j.neurol.2016.05.006. Epub 2016 Nov 9. Review.

PMID:
27838091
36.

CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy.

Pignolet B, Schwab N, Schneider-Hohendorf T, Bucciarelli F, Biotti D, Averseng-Peaureaux D, Outteryck O, Ongagna JC, de Sèze J, Brochet B, Ouallet JC, Debouverie M, Pittion S, Defer G, Derache N, Hautecoeur P, Tourbah A, Labauge P, Castelnovo G, Clavelou P, Berger E, Pelletier J, Rico A, Zéphir H, Laplaud D, Wiertlewski S, Camu W, Thouvenot E, Casez O, Moreau T, Fromont A, Vukusic S, Papeix C, Vermersch P, Comabella M, Lebrun-Frenay C, Wiendl H, Brassat D; BIONAT, SFSEP, and BEST-MS networks.

Neurology. 2016 Dec 6;87(23):2491-2494. Epub 2016 Nov 4. No abstract available.

PMID:
27815407
37.

Benefits from an autobiographical memory facilitation programme in relapsing-remitting multiple sclerosis patients: a clinical and neuroimaging study.

Ernst A, Sourty M, Roquet D, Noblet V, Gounot D, Blanc F, de Seze J, Manning L.

Neuropsychol Rehabil. 2018 Oct;28(7):1110-1130. doi: 10.1080/09602011.2016.1240697. Epub 2016 Oct 9.

PMID:
27718890
38.

Giving meaning to illness: An investigation of self-defining memories in patients with relapsing-remitting multiple sclerosis patients.

Voltzenlogel V, Ernst A, de Sèze J, Brassat D, Manning L, Berna F.

Conscious Cogn. 2016 Oct;45:200-209. doi: 10.1016/j.concog.2016.09.010. Epub 2016 Sep 19.

PMID:
27656786
39.

MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.

Tourbah A, Lebrun-Frenay C, Edan G, Clanet M, Papeix C, Vukusic S, De Sèze J, Debouverie M, Gout O, Clavelou P, Defer G, Laplaud DA, Moreau T, Labauge P, Brochet B, Sedel F, Pelletier J; MS-SPI study group.

Mult Scler. 2016 Nov;22(13):1719-1731. Epub 2016 Sep 1.

40.

Exploratory Phase II Trial to Evaluate the Safety and the Antiepileptic Effect of Pitolisant (BF2.649) in Refractory Partial Seizures, Given as Adjunctive Treatment During 3 Months.

Collart Dutilleul P, Ryvlin P, Kahane P, Vercueil L, Semah F, Biraben A, Schwartz JC, De Seze J, Hirsch E, Collongues N.

Clin Neuropharmacol. 2016 Jul-Aug;39(4):188-93. doi: 10.1097/WNF.0000000000000159.

PMID:
27223666
41.

Neuromyelitis optica spectrum disorder (NMOSD): A new concept.

de Sèze J, Kremer L, Collongues N.

Rev Neurol (Paris). 2016 Apr-May;172(4-5):256-62. doi: 10.1016/j.neurol.2016.03.003. Epub 2016 May 4. Review.

PMID:
27157418
42.

An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica.

Collongues N, de Seze J.

Ther Adv Neurol Disord. 2016 May;9(3):180-8. doi: 10.1177/1756285616632653. Epub 2016 Mar 23. Review.

43.

Should a psychotic or manic episode be considered an early manifestation of Multiple Sclerosis? A multiple case study.

Berna F, Blanc F, Lebrun C, Castelnovo G, Clerc C, Debouverie M, Jouvenoz D, Marcel-Viallet M, Zaenker C, Zephir H, Vidailhet P, De Sèze J.

Mult Scler Relat Disord. 2016 Mar;6:93-6. doi: 10.1016/j.msard.2016.02.004. Epub 2016 Feb 12.

PMID:
27063631
44.

Functional and structural cerebral changes in key brain regions after a facilitation programme for episodic future thought in relapsing-remitting multiple sclerosis patients.

Ernst A, Sourty M, Roquet D, Noblet V, Gounot D, Blanc F, De Seze J, Manning L.

Brain Cogn. 2016 Jun;105:34-45. doi: 10.1016/j.bandc.2016.03.007. Epub 2016 Apr 2.

PMID:
27045451
45.

Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study.

Peyro Saint Paul L, Creveuil C, Heinzlef O, De Seze J, Vermersch P, Castelnovo G, Cabre P, Debouverie M, Brochet B, Dupuy B, Lebiez P, Sartori É, Clavelou P, Brassat D, Lebrun-Frenay C, Daplaud D, Pelletier J, Coman I, Hautecoeur P, Tourbah A, Defer G.

J Neurol Sci. 2016 Apr 15;363:69-76. doi: 10.1016/j.jns.2016.02.012. Epub 2016 Feb 6.

PMID:
27000224
46.

False positivity of anti aquaporin-4 antibodies in natalizumab-treated patients.

Cohen M, De Sèze J, Marignier R, Lebrun C.

Mult Scler. 2016 Aug;22(9):1231-4. doi: 10.1177/1352458516630823. Epub 2016 Feb 11.

PMID:
26869528
47.

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.

Barbin L, Rousseau C, Jousset N, Casey R, Debouverie M, Vukusic S, De Sèze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Créange A, Labauge P, Magy L, Defer G, Foucher Y, Laplaud DA; CFSEP and OFSEP groups.

Neurology. 2016 Feb 23;86(8):771-8. doi: 10.1212/WNL.0000000000002395. Epub 2016 Jan 29.

48.

Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis.

Chan A, de Seze J, Comabella M.

CNS Drugs. 2016 Jan;30(1):41-51. doi: 10.1007/s40263-015-0299-y. Review.

49.

Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes.

Juryńczyk M, Weinshenker B, Akman-Demir G, Asgari N, Barnes D, Boggild M, Chaudhuri A, D'hooghe M, Evangelou N, Geraldes R, Illes Z, Jacob A, Kim HJ, Kleiter I, Levy M, Marignier R, McGuigan C, Murray K, Nakashima I, Pandit L, Paul F, Pittock S, Selmaj K, de Sèze J, Siva A, Tanasescu R, Vukusic S, Wingerchuk D, Wren D, Leite I, Palace J.

J Neurol. 2016 Jan;263(1):140-9. doi: 10.1007/s00415-015-7952-8. Epub 2015 Nov 3.

50.

Anti-pseudo-PCNA type 1 (anti-SG2NA) pattern: Track down Cancer, not SLE.

Guffroy A, Dima A, Nespola B, Poindron V, Sibilia J, Herbrecht R, De Sèze J, Habersetzer F, Andres E, Quoix E, Ohlmann P, Cribier B, Langer B, Martin T, Pasquali JL, Goetz J, Korganow AS.

Joint Bone Spine. 2016 May;83(3):330-4. doi: 10.1016/j.jbspin.2015.07.002. Epub 2015 Oct 1.

PMID:
26433710

Supplemental Content

Loading ...
Support Center